BMYBristol Myers Squibb

Health care · Pharmaceuticals · NYSE

Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. 10-K, Item 1

Employees: 32,500
Headquarters: Princeton, NJ
CEO: Christopher S. Boerner
Next results: around Feb 4, 2027

Compare with peers → Embed

RevenueFY2016–25 $48.2B−0.2% FY2024: $48.3B 10-K FY2025 · XBRL Net incomeFY2016–25 $7.1B FY2024: −$8.9B 10-K FY2025 · XBRL Free cash flowFY2016–25 $12.8B−7.9% FY2024: $13.9B 10-K FY2025 · XBRL

What changed

10-K filed Feb 11, 2026 against Feb 12, 2025

Area	What changed	Source
Risk factors	7 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Accounting checks	10 other checks clear	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	2 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 11, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-12. Quoted as filed.

The U.S. and other countries have recently imposed, and may continue to impose, new tariffs. While pharmaceuticals are largely exempt from the tariffs imposed in 2025, such exemptions may be terminated or may not apply to any future tariffs. In accordance with the U.S. Government Agreement, BMS will receive certain U.S. tariff relief…
10-K, Item 1A

All 7 new paragraphs →

Accounting checks

latest 10-K

10 of 10 clear 0 worth a look. Checks, not verdicts.

✓
Receivables +6.4% vs revenue -0.2% (+6.7 pts)
✓
Cash from operations $14.2B vs net income $7.1B (FY ending 2025-12-31)
✓
Inventory +5.2% vs revenue -0.2% (+5.4 pts)
✓
Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Oct 29, 20268-K Quarterly results, Regulation FD disclosure 8-K items 2.02, 7.01
Oct 29, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on BMY in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/BMY/export.csv") into a cell.